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Summary
Gaucher disease is a lysosomal storage disorder
caused by deficient glucocerebrosidase activity. We
have previously shown that the cellular activity of the
mostcommonGaucherdisease-associatedglucocere-
brosidase variant, N370S, is increased when patient-
derived cells are culturedwith the chemical chaperone
N-nonyl-deoxynojirimycin. Chemical chaperones sta-
bilize proteins against misfolding, enabling their traf-
ficking from the endoplasmic reticulum. Herein, the
generality of this therapeutic strategy is evaluated
with other glucocerebrosidase variants and with addi-
tional candidate chemical chaperones. Improved
chemical chaperones are identified for N370S glu-
cocerebrosidase. Moreover, we demonstrate that
G202R, a glucocerebrosidase variant that is known to
be retained in the endoplasmic reticulum, is also ame-
nable to chemical chaperoning. The L444P variant is
not chaperoned by any of the active site-directed mol-
ecules tested, likelybecause thismutationdestabilizes
a domain distinct from the catalytic domain.
Introduction
Gaucher disease is the most common lysosomal stor-
age disorder, with an estimated incidence of 1 in
60,000 in the general population [1] and 1 in 800 among
the Ashkenazi Jewish population [2]. Activity-com-
promising mutations in glucocerebrosidase (GC, acid
b-glucosidase, glucosylceramidase, D-glucosyl-N-acyl-
sphingosine glucohydrolase), a lysosomal hydrolase
that converts glucosylceramide to ceramide and glu-
cose, lead to the accumulation of glucosylceramide in
the lysosomes of monocyte-macrophage cells—the
hallmark of Gaucher disease (see Figure 1 for the struc-
ture of glucosylceramide 1). Glucosylceramide storage
results in hepatomegaly, splenomegaly, anemia, bone
lesions, and central nervous system involvement (re-
viewed in [3]). Patients without central nervous system
symptoms are classified as type 1, whereas those with
central nervous system symptoms are classified as ei-
*Correspondence: jkelly@scripps.eduther type 2 (acute infantile) or type 3 (juvenile or early-
adult onset).
Current treatment approaches for Gaucher disease in-
clude replacement of the defective enzyme with re-
combinant enzyme infusions or inhibition of glucosylcer-
amide production [4]. Type 1 disease can be managed
with enzyme replacement therapy [5]; however, the treat-
ment is costly [6], and the enzyme is unable to cross the
blood-brain barrier to alleviate the central nervous sys-
tem symptoms of severe disease. A drug that inhibits
the production of glucosylceramide (N-butyl-deoxynojir-
imycin 22, Figure 1), thus decreasing the substrate load
on GC, has recently become available to type 1 patients.
However, its efficacy against central nervous system
symptoms is unknown [7, 8]. Since this ‘‘substrate depri-
vation therapy’’ acts on glucosylceramide biosynthesis
rather than on GC, other cellular pathways utilizing glu-
cosylceramide are likely to be adversely affected by the
drug, which may explain its side effects [7, 8].
Only small increases in residual lysosomal enzyme ac-
tivity may be needed to avoid storage diseases. For ex-
ample, mutations that abolish b-hexosaminidase activity
result in severe Sandhoff disease and early death [9],
whereas chronic adult forms occur with residual enzyme
activity levels of 3%–6% of normal, while completely un-
affected individuals have been identified with only 9%–
10% of normal levels [10]. This critical threshold for de-
velopment of disease phenotype [11] is recapitulated
with Gaucher disease. Schueler and colleagues have
found that GC activity can be reduced to 11%–15% of
normal levels before substrate storage commences in
a tissue culture model for Gaucher disease [12]. In pa-
tients receiving enzyme replacement therapy, only
a very small fraction of recombinant GC remains hours
after intravenous infusion, yet the extent of enzyme ac-
tivity elevation is sufficient to reduce hepatosplenome-
galy and bone crises and to improve blood counts [13].
Therefore, slight increases in the activity of mutant lyso-
somal enzymes appear to be clinically useful.
Misfolded GC variants are expected to bind to protein
chaperones in the endoplasmic reticulum (ER). Sus-
tained binding leads to proteasomal degradation of the
enzyme regardless of catalytic competence in the lyso-
somal environment. Binding of active site-directed
‘‘chemical chaperones’’ (also called ‘‘pharmacological
chaperones’’) could potentially stabilize catalytically
competent GC variants at neutral pH in the ER, allowing
them to fold and pass the quality control checks for traf-
ficking to the lysosome. The GC variants are expected to
be stable upon chemical chaperone dissociation due to
the high substrate concentrations and low pH in the ly-
sosome. As long as lysosomal GC has reduced affinity
for the chemical chaperones relative to the abundant
glucosylceramide, inhibition will be minimal, and the en-
zyme will degrade the stored glucosylceramide.
Chemical chaperones have been shown to increase
the trafficking and cellular activity of several disease-
associated mutant proteins (reviewed in [14, 15]). Pre-
vious studies have identified ligands that chaperone
a subset of the mutant enzymes responsible for
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1236Figure 1. Compounds Evaluated in This Study
Chemical structures of D-glucosylceramide (1), glucose derivatives (2–9), C-glycoside analogs (10–21), DNJ analogs (22–28), and additional
compounds that may offer promise as GC chaperones (29–34).
Chemical Chaperones for Gaucher Disease
1237lysosomal storage diseases, including Fabry [16], Tay-
Sachs, and Sandhoff diseases [9], as well as GM1-
gangliosidosis [17]. We have shown that the most
common Gaucher disease-associated GC variant,
N370S, is amenable to chemical chaperoning by N-
nonyl-deoxynojirimycin 23 [18]. Chemical chaperoning
combines the benefits of a small-molecule approach—
oral bioavailability, cell permeability, and the potential
to cross the blood-brain barrier—with the specificity of
targeting GC selectively.
Herein, we explore the generality of chemical chaper-
oning for increasing the lysosomal activity of other GC
variants associated with Gaucher disease and evaluate
a broad spectrum of candidate chemical chaperones.
Results
The activity of GC variants, including N370S, G202R,
and L444P (which both exhibit a more severe disease
phenotype than N370S [19, 20]), was assessed in
patient-derived cell lines after incubation with candidate
chemical chaperones for 5 days. A small molecule will
be described as activating when GC activity is elevated
above that of untreated cells by at least 10% and inhib-
itorywhen GC activity is reduced below that of untreated
cells by at least 10%. Activity changes of less than 10%
were typically not reproducible in independent experi-
ments. Since the small molecules being tested are envi-
sioned to bind to the active site of GC, it is expected that
even activating compounds may become inhibitory at
higher concentrations. The concentration range in the
media over which a compound is activating but not in-
hibitory is its window of utility. This window of utility in-
cludes the concentrations at which a compound is max-
imally and submaximally activating.
Residual Activities of GC Variants
There are large discrepancies in the reported residual ac-
tivity of GC variants due, in part, to the diversity of assay
conditions employed [21]. Hence, the residual GC activ-
ities of the patient-derived fibroblast cell lines employed
in this study were determined by using the same assay
employed in the chemical chaperoning analyses (Table 1).
The cells are washed and then treated with artificial sub-
strate in acidic solution without lysing the cells or adding
any additional detergents or activators. The activity is
quantified with respect to total cellular protein to normal-
ize for cell density and then compared to wild-type (WT)
activity. The residual activity is a function of the lyso-
somal GC concentration and the specific activity of the
variant. Under these assay conditions, N370S has higher
residual activity (w32%) than G202R (w10%) and L444P
(w12%). In lysed cells, Grace and colleagues have ob-
served that N370S activity is greatly stimulated by deter-
gents and bile salts [20]. Since the activity of individual
GC variants is highly dependent on the assay conditions,
all chemical chaperoning activity data are reported nor-
malized to untreated cells of the same type rather than
normalized to WT activity.
The Ability of Glucose Analogs and C-Glycosides
to Chaperone GC
A series of glucose analogs (compounds 2–9, Figure 1)
were prepared as potential chemical chaperones ofGC based on their structural resemblance to glucosyl-
ceramide 1. While these compounds are much more sol-
uble than the parent compound and are nontoxic in cells
at concentrations as high as 200 mM, they do not alter
GC activity in WT, N370S, G202R, and L444P cell lines
(data not shown). These compounds may be hydrolyzed
by the cell, explaining their inactivity.
In order to eliminate the possibility of glycosidic bond
hydrolysis, we prepared a series of glucose-based
b-substituted C-glycosides (compounds 10–15, Figure 1),
in which the anomeric oxygen is replaced by a carbon
atom to create a nonepimerizable structure. The com-
pounds composed of unbranched alkyl chains (10–14)
have no chaperoning activity in the four cell lines uti-
lized. The branched and highly hydrophobic glucosyl-
ceramide mimic 15 inhibits GC activity at relatively low
concentrations (5 mM) in all cell lines. The binding activity
of the branched compound is most likely due to the long,
branched alkyl chain rather than the glucose-based core
since galactose-based 17 contains a long, branched
chain and is also inhibitory, while the less substituted
1,2-dideoxy-D-glucose 16 with a long, linear alkyl chain
exhibits no activity in any of the cell lines.
Since the iminosugar nonyl DNJ 23 is a known chem-
ical chaperone for GC [18], we also prepared a series of
iminosugar C-glycosides. Iminosugar 21 slightly en-
hances GC activity in G202R cells at concentrations of
10–20 mM, but, in general, this class of compounds did
not show significant activity in any of the cell lines. In
summary, neither the glucose analogs nor the C-glyco-
side compounds seem to be effective chemical chaper-
ones for GC.
The Effect of Alkylated DNJ Analogs on GC Activity
We have previously reported that culturing N370S cells
with the alkylated DNJs 23 and 25 (Figure 1) increases
GC variant activity [18]. Chemical chaperone 23 in-
creases N370S activity by 65% (light-blue line, Figure
2A), as does 25, although the latter exhibits a much
wider window of utility (orange line, Figure 2A). These
compounds similarly increase GC activity in a G202R
cell line (Table 2). Chemical chaperone 23 functions
over a concentration range of 0.5–10 mM and is inhibitory
at concentrations greater than 30 mM. Chaperone 25 in-
creases G202R activity over a concentration range of
25–50 mM and is not inhibitory at concentrations as
high as 100 mM. Both compounds modestly increase
Table 1. The Residual Activities of GC Variants
Glucocerebrosidase
Residual Activity
per Total Protein
WT 100%
N370S 32% 6 7%
G202R 10% 6 5%
L444P 12% 6 7%
Activities of GC variants in patient-derived cells were measured as
described by using 4-methylumbelliferyl-b-D-glucopyranoside with-
out lysing the cells or adding activators and are reported with re-
spect to total cellular protein to normalize for cell density. The resid-
ual activity is a function of lysosomal concentration and the specific
activity of GC. Residual activities of N370S, G202R, and L444P are ex-
pressed as percentage of WT activity. Data shown are the average6
standard deviation of three or more independent experiments.
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compound increases the activity of L444P, but both
are inhibitory at concentrations exceeding 1 mM.
Previous studies show that 22, the substrate depriva-
tion drug discussed above, does not enhance the cellu-
lar activity of N370S and is not inhibitory at concentra-
tions as high as 100 mM (gray line, Figure 2A) [18]. An
analogous behavior was observed in WT, G202R, and
L444P GC cell lines.
We have previously reported that DNJ analogs con-
taining long alkyl chains, e.g., 26, inhibit N370S at mM
concentrations (dark-blue filled circles, Figure 2A) [18].
Examination of the activity of 26 at submicromolar con-
Figure 2. The Effect of DNJ Analogs on Gaucher Disease-Associ-
ated Glucocerebrosidase Variants
(A) The influence of DNJ analogs on cellular N370S activity. Tripli-
cate wells of N370S cells were incubated with the test compounds
for 5 days before being assayed for GC activity. The activity of trea-
ted cells was normalized against the activity of untreated cells. The
dashed line represents the activity of untreated cells. Data shown
are the average of three experiments, and the error bars corre-
spond to the standard deviation. The inset details the chaperoning
activity of 23, 26, and 28 over the concentration range of 0–2 mM.
(B) The influence of compound 27 on WT, N370S, G202R, and
L444P cellular GC activity. Triplicate wells of the indicated cell
type were incubated with 27 for 5 days before being assayed for
GC activity. The activity of treated cells was normalized against
the activity of untreated cells of the same type. The dashed line
represents the activity of untreated cells. Data shown are the aver-
age of three experiments, and the error bars correspond to the
standard deviation.centrations reveals that it is slightly activating (inset, Fig-
ure 2A). Cellular N370S activity is increased by 20% at
concentrations lower than 100 nM. G202R activity is in-
creased by 30% over a concentration range of 50–100
nM and is inhibited at higher concentrations. Neither
WT nor L444P is activated by low concentrations of
26, but both are inhibited in the micromolar range.
Increasing the length of the alkyl chain correspond-
ingly decreases apparent Ki and IC50 values in vitro
[22]. It is believed that increasing the hydrophobicity of
the alkyl group on DNJ also helps target these molecules
to cell membranes in vivo, and thus affects drug locali-
zation [23]. However, the fluorinated derivative 24 (pur-
ple line, Figure 2A) exhibits activity profiles that resem-
ble those of structurally similar, nonfluorinated 23 and
25 (light-blue and orange lines, respectively, Figure
2A). G202R activity is maximally increased by 70% by
24 over a concentration range of 25–50 mM, with a win-
dow of utility of 10–100 mM, whereas L444P is inhibited
at concentrations greater than 1 mM (Table 2).
Terminating the DNJ alkyl chain with a hydrophobic
adamantyl group results in very active compounds.
Compound 27 confers a 140% increase in the cellular
activity of N370S with a wide window of utility (red line,
Figures 2A and 2B), and it is the most active N370S
chaperone we have discovered thus far. Notably,
G202R cells treated with 27 exhibit a maximal activity in-
crease of 270%—the highest activity increase observed
in any cell line (blue line, Figure 2B). The compound also
has a broad window of utility and is not inhibitory at con-
centrations as high as 150 mM. Chaperone 27 maximally
increases the activity of WT by 30% with a broad win-
dow of utility (green line, Figure 2B). In contrast, 27 inhib-
its L444P activity at concentrations greater than 5 mM
(orange line, Figure 2B). Interestingly, amide-linked 27
is strongly activating, while the equivalent ether-linked,
adamantly capped compound 28 is strongly inhibitory
(red and green lines, respectively, Figure 2A), which
may be a consequence of intracellular concentration
or distribution. N370S (green line, Figure 2A, inset) and
G202R are both slightly activated by 28 at very low con-
centrations (20% at 10–500 nM); however, all cell lines
are strongly inhibited at concentrations greater than 1
mM. Further studies are needed to understand how the
subtle structural difference between 27 and 28 results
in two very different activity profiles.
With the exception of 22, all of the DNJ analogs tested
in this study chaperone N370S and G202R. Of all the
DNJ analogs tested, 27displays a significantly improved
activity profile and represents a substantial improve-
ment over previously reported compounds. The L444P
GC variant is unique in that it is not chaperoned by any
of the DNJ analogs depicted in Figure 1 and is at least
50% inhibited at concentrations greater than 25 mM by
all of the analogs, except 22.
The Enhancement of GC Activity by Other
Structurally Distinct Compounds
DNJ-based compounds lack a substituent at the
anomeric carbon and thus do not specifically mimic
the a or b conformation of disaccharides or glycolipids,
which could compromise their selectivity for GC over
other enzymes. DNJ-based GC inhibitors are known to
bind to other enzymes, including ER glycoprotein
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Compound Wild-Type N370S G202R L444P
22 No increase No increase No increase No increase
23 25% 6 10% 65% 6 20% 60% 6 10% No increase
24 30% 6 10% 80% 6 15% 70% 6 15% No increase
25 25% 6 10% 60% 6 10% 70% 6 10% No increase
26 No increase 20% 6 10% 30% 6 10% No increase
27 30% 6 15% 140% 6 20% 270% 6 30% No increase
28 No increase 20% 6 10% 20% 6 10% No increase
29 10% 6 5% 10% 6 5% No increase No increase
30 15% 6 10% 35% 6 10% 50% 6 15% No increase
31 25% 6 10% 55% 6 10% 220% 6 10%a No increase
32 Not tested 45% 6 5%b 220% 6 5%b Not tested
33 40% 6 10% 50% 6 10% 70% 6 5% No increase
34 25% 6 10% 20% 6 10% 50% 6 10% No increase
Analogs were evaluated over the concentration range of 10 nM–100 mM. Each compound was assayed at least three times, independently, and
each experiment was conducted in triplicate. Triplicate wells within an experiment typically show less than 5% standard deviation. Data shown
are the average 6 standard deviation of three or more independent experiments.
a Compound was tested from 10 nM to 150 mM in this cell line.
b Data shown are the average 6 standard deviation of one triplicate experiment because of limited compound supply.processing enzymes [24]—a potential problem for long-
term administration. Additional iminosugar structures
(29–34), including known GC inhibitors such as castano-
spermine 29, alkylated isofagomine 32, and the known
glucosyltransferase inhibitor 1-phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (PDMP) 34, were there-
fore evaluated as potential chemical chaperones of GC.
Simple alkylated nitrogen heterocycles have been
shown previously to be useful for N370S chemical
chaperoning based on the hypothesis that the positively
charged nitrogen can form an ion pair with carboxylate
nucleophiles in the GC active site [18]. Morpholine ana-
log 30 and piperazine analog 33were found to maximally
increase N370S activity by 35% (30 mM) and 50% (5 mM),
respectively, with broad windows of utility of 5–50 mM
(Table 2). These minimally substituted heterocycles
also increase G202R activity byw60% (blue and green
lines, Figure 3). Compounds 30 and 33 maximally acti-
Figure 3. The Influence of Alternative Chemical Structures on Cel-
lular G202R Activity
Triplicate wells of G202R cells were incubated with indicated com-
pounds for 5 days before being assayed for GC activity. The activity
of treated cells was normalized against the activity of untreated
cells. The dashed line represents the activity of untreated cells.
Data shown are the average of triplicate wells for a representative ex-
periment, and the error bars correspond to the standard deviation.vate WT by 15% and 40%, respectively, at a concentra-
tion of 25 mM, but they do not activate L444P. These
compounds are inhibitory at concentrations greater
than 60 mM in WT, G202R, and L444P cell lines.
PDMP 34 was designed to resemble the GC substrate
glucosylceramide and is a known inhibitor of glucosyl-
ceramide synthesis [25, 26]. Compound 34 activates
GC and shows the same maximal activity in G202R cells
as the structurally related 30, but at a lower concentra-
tion (red line, Figure 3). Compound 34 is slightly activat-
ing in WT and N370S cells (20%–25%) at concentrations
of 10–20 mM, but it has no effect on L444P cells.
1-N-iminosugars such as the isofagomine derivative
32 are reported to have greater selectivity for b-glycosi-
dases than DNJ-type iminosugars, which are generally
more selective for a-glycosidases [27]. DNJ-type imino-
sugars place a positive charge at the position of the glu-
copyranose ring oxygen in contrast to isofagomine-type
iminosugars, which place the positive charge at the
anomeric position. It is believed that b-glycosidases uti-
lize the latter reaction intermediate whereas a-glycosi-
dases do not. Compound 32 enhances N370S activity
(45% at 15 mM) but has a narrow window of utility (5–
30 mM). Its window of utility in G202R cells is much
broader, where it maximally increases enzyme activity
by 220% (orange line, Figure 3).
N-octyl-2,5-dideoxy-2,5-imino-D-glucitol 31 is a fura-
nose-based analog of DNJ and a known glycosidase in-
hibitor [28]. This five-membered ring azasugar adopts
a half-chair conformation and is envisioned to be a tran-
sition state mimic. Treatment with 31 leads to a 55%
maximal increase in N370S activity over a concentration
range of 15–30 mM, with a window of utility of 5–100 mM.
Compound 31 has the widest window of utility in G202R
cells and is not inhibitory at concentrations as high as
150 mM (purple line, Figure 3), although it becomes toxic
to all of the cell lines at concentrations greater than 150
mM. The G202R response is similar to the cellular activity
increase observed with the most active DNJ analogs.
Compound 31 increases WT activity by 25% and is not
inhibitory at concentrations less than 150 mM. L444P is
neither activated nor inhibited by 31 (Table 2).
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cycle known to inhibit WT and mutant GCs with low mi-
cromolar IC50 values [19, 29]. Compound 29 is neither
activating nor significantly inhibitory (less than 30% inhi-
bition) in any of the cell lines at concentrations as high as
100 mM.
These studies demonstrate that iminosugars contain-
ing an alkylated tertiary nitrogen (23, 30–33) are chemi-
cal chaperones for GC, whereas compounds that con-
tain similar alkyl chains, but lack the tertiary nitrogen
(6, 7, 9, 13, 14, 20, 21), are not. The non-DNJ-based imi-
nosugars (30–34) are active in WT, N370S, and G202R
cells, but not in L444P cells. The azafuranose 31 and iso-
fagomine 32 structures show great promise as starting
points for the development of improved GC chemical
chaperones.
The Kinetics of Chemical Chaperone Action
Longer time courses were evaluated to provide kinetic
data for the most effective chemical chaperones.
G202R patient fibroblasts were incubated with 27, 31,
or 32 (50 mM) for 14 days, and cellular G202R GC activity
was assessed at various time points throughout the ex-
periment. Cells incubated with 27 and 32 reached max-
imal activity within 4 days of treatment, and activity
levels remained constant for the duration of this experi-
ment (blue and red lines, Figure 4A). Cells incubated with
Figure 4. Chemical Chaperoning during a Prolonged Period of
Time
(A) The influence of culture duration on the chemical chaperoning
effect of 27, 31, and 32. G202R cells were incubated with the com-
pound (50 mM) for the indicated amount of time before being as-
sayed for GC activity. The activity of treated cells was normalized
against the activity of untreated cells. Representative data are
shown.
(B) The influence of washout duration on the chemical chaperoning
effect of 27, 31, and 32. G202R cells were incubated with 50 mM of
compound for 7 days before a washout time course was initiated.
The activity of treated cells was normalized against the activity of
untreated cells. Representative data are shown.31 took slightly longer (w6–8 days) to reach maximal ac-
tivity levels (green line, Figure 4A).
Since these compounds are inhibitors of GC, the tim-
ing of activity measurements could have an impact on
the detected activity levels. To investigate this possibil-
ity, G202R patient fibroblasts were incubated with 27,
31, or 32 (50 mM) for 7 days before commencing a wash-
out time course (Figure 4B). The activity increases
caused by 27 and 31 have a similar pattern of decline
upon removal of the compound (blue and green lines,
Figure 4B), although the increase resulting from 31 per-
sists longer. The activity of cells incubated with 32 in-
creases for 4 days upon removal of the compound, im-
plying that 32 is partially inhibiting GC in the lysosome
at the concentration (50 mM) utilized (red line, Figure
4B). The differences in the chemical chaperoning activity
profiles of these compounds can be, in part, explained
by the concentrations employed. The 50 mM concentra-
tion utilized is below the concentration required for max-
imal activity of 31, at the concentration required for max-
imal activity of 27, and above the concentration required
for maximal activity of 32. Thus, removing the com-
pound leads to an activity decrease in the case of 27
and 31 and to an activity increase in the case of 32, ow-
ing to partial GC inhibition.
The Influence of GC Chemical Chaperones
on the Activity of Other Lysosomal Enzymes
In order to investigate the specificity of the chemical
chaperones for GC, the activity of other lysosomal
hydrolases was examined concurrently. G202R cells
were treated with 21 (50 mM), 27 (50 mM), 31 (50 mM),
32 (50 mM), or 34 (20 mM) for 5 days, and the cell lysates
were screened for b-hexosaminidase, b-glucuronidase,
Figure 5. The Influence of Glucocerebrosidase Chemical Chaper-
ones on the Activity of Other Lysosomal Hydrolases
G202R cells were treated with 21 (50 mM), 27 (50 mM), 31 (50 mM), 32
(50 mM), or 34 (20 mM) for 5 days, and the cell lysates were screened
for b-hexosaminidase, b-glucuronidase, b-galactosidase, a-galac-
tosidase A, a-glucosidase, and acid phosphatase activity in tripli-
cate. The activity of treated cells was normalized against the activ-
ity of untreated cells. Data shown are the average of triplicate wells
for a representative experiment, and the error bars correspond to
the standard deviation.
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acid phosphatase activity (Figure 5). Unlike G202R GC,
the activity of these other hydrolases remains generally
unaffected by the chemical chaperones. These results
are significant in that the representative compounds
did not influence the activity of other WT lysosomal en-
zymes. Only a-glucosidase activity was significantly in-
creased by chemical chaperone 27, which is not surpris-
ing, as this compound should not have selectivity for a
b-glucosidase such as GC over an a-glucosidase. As hy-
pothesized, isofagomine 32 is significantly more selec-
tive for GC than lysosomal a-glucosidase. While further
experiments must be performed to ascertain whether
these compounds interact with other proteins and influ-
ence cellular pathways, it appears that this subset of
compounds is not chaperoning lysosomal hydrolases
nonspecifically.
Discussion
We have previously demonstrated an increase in the cel-
lular activity of N370S GC in response to chemical chap-
erone treatment [18]. While not presented herein, we
now know that alkylated DNJ binding to N370S GC cor-
rects the neutral pH folding deficiency of this variant in
the ER, allowing it to be trafficked to the lysosome
(A.R.S., unpublished data). It is presumed that the other
compounds discovered herein and referred to as chem-
ical chaperones also function by this mechanism; how-
ever, this remains to be proven. It is not inconceivable
that some of these could function by influencing cellular
folding pathways, and not by binding to GC.
In this study, we explored the generality of utilizing
chemical chaperones in WT, N370S, G202R, and
L444P GC cell lines derived from Gaucher patients.
The mutation-associated reduction of cellular GC activ-
ity may stem from reduced catalytic activity and/or re-
duced enzyme concentration in the lysosome. Enzyme
activity is reduced by mutations that impair catalysis,
activator binding, or substrate binding [20]. The benefit
of chemical chaperoning may be limited in these cases
since increasing the concentration of these mutant en-
zymes in the lysosome may not significantly increase
substrate catabolism. Mutations decrease the lyso-
somal enzyme concentration of some GC variants be-
cause compromised folding in the ER results in non-
native conformations and proteasomal degradation
[30] regardless of catalytic competence. Small increases
in the trafficking of catalytically active variants may lead
to substantial increases in lysosomal GC activity.
The N370S variant has decreased affinity (2- to 10-
fold) for DNJ analogs [18, 20, 22], suggesting that this
mutation may affect substrate binding and catalytic ac-
tivity. A recently solved crystal structure of GC locates
the N370S mutation to a helix near, but not within, the
active site [31]. Of the compounds tested above,
the DNJ-based inhibitors 23–25 and 27 are among the
best chemical chaperones, exhibiting increases in
N370S activity of approximately 2- to 2.5-fold. While
this increase may seem modest, it may be sufficient to
ameliorate disease (see below).
The G202R mutation is associated with a more severe
disease course relative to N370S, consistent with its re-
duced cellular GC activity ([32] and Table 1). Zimmer andcolleagues report that patient fibroblasts containing the
G202R mutation have 13% residual activity when as-
sayed by using the natural substrate [32]. This is in
agreement with the residual activity that we measured
by using the intact cell assay conditions and much
higher than the 1% residual activity value reported by
Grace and colleagues for G202R expressed in insect
cells and assayed by using a different method [19].
The G202R mutation is in the same domain of the protein
as the active site, but it is located at the end of a helix
much farther from the active site than N370S [31]. The
G202R mutation is reported to be retained in the ER,
making it a logical mutation to employ to test the hy-
pothesis that chemical chaperones increase GC activity
by increasing the trafficking of nascent protein from the
ER to the lysosome [32].
Chemical chaperones that increase the activity of
G202R also increase the activity of N370S. In many
cases (27, 31, 32), the relative activity increase observed
with G202R is much greater than that of N370S. This is
consistent with the hypothesis that the G202R mutation
destabilizes GC but does not disrupt the catalytic activ-
ity of the folded protein; hence, the chemical chaperone
can induce folding into an active enzyme that is traf-
ficked. Lin and colleagues have reported that the known
GC inhibitor, N-octyl-b-valienamine, is a chemical chap-
erone of the F213I Gaucher disease variant [33], a mu-
tation that localizes to the helix near G202 [31]. Col-
lectively, the WT, N370S, G202R, and F213I variants
demonstrate that it is possible to chaperone GC variants
localized to the active site domain.
The severe L444P mutation is the most common mu-
tation leading to central nervous system pathology [21].
This mutation is located in a separate Ig-like domain of
the protein, remote from the domain containing the ac-
tive site [31]. It is possible that the misfolding of this mu-
tant protein is so severe that binding of the putative
chaperone does not occur in the ER. It is more probable
that the chemical chaperones do bind to L444P in the
ER; however, stabilization of the active site domain of
this protein may not influence the misfolding of the do-
main harboring the mutation. Therefore, sustained bind-
ing of protein chaperones to the Ig-like domain in the ER
may trigger protein degradation despite stabilization of
the active site domain by chemical chaperones targeted
to the latter. Several of the compounds inhibit L444P ac-
tivity, which indicates that they have the ability to bind to
the active site of the L444P enzyme that is synthesized
and trafficked to the lysosome. While a proline substitu-
tion can severely compromise folding, we have found
that culturing cells at a reduced temperature increases
the activity of L444P GC 3- to 4-fold (A.R.S., unpublished
data), demonstrating that the activity of this variant can
be restored. Small molecules that have the ability to bind
in the Ig-like domain of GC, rather than active site-
directed molecules, might be required to stabilize this
mutation in the ER. Further studies must be undertaken
to test this hypothesis.
Wild-type cells frequently exhibited slight increases in
relative activity when treated with small molecules that
are chemical chaperones in N370S and G202R cell lines.
The ability of WT GC to be chemically chaperoned to
some extent implies that some of the WT enzyme is de-
graded under cell culture conditions, consistent with the
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misfolds and is degraded. It is reasonable that the rela-
tive maximal activity of chemical chaperones in WT cells
is much lower than in N370S and G202R cells owing to
evolutionary optimization of the WT sequence.
Heterozygous individuals with abnormal GC activity
are not clinically affected, implying that WT levels of en-
zyme activity are not needed to prevent disease. The
2.4-fold activity increase observed by chemical chaper-
one treatment of N370S cells may be sufficient to ame-
liorate disease, given that the residual activity of this mu-
tation is quite high. Doubling N370S activity may be
sufficient to raise activity levels above the ‘‘critical
threshold’’ for the development of disease phenotype.
The residual activity of G202R determined by using our
assay conditions is in agreement with the 13% reported
by Zimmer and colleagues [32]. The 3.2- to 3.7-fold in-
crease in G202R activity observed when these cells
are treated with chemical chaperones 27, 31, and 32
may also be sufficient to be clinically useful.
While the C-glycosides tested were designed to have
fixed stereochemistry that mimics glucosylceramide,
they are not transition state mimetics and are not effec-
tive GC chemical chaperones. In contrast to theC-glyco-
sides, octyl or nonyl-alkylated iminosugars such as DNJ,
morpholine, piperazine, isofagomine, and 2,5-dideoxy-
2,5-imino-D-glucitol are active in multiple GC variant
cell lines. Examination of a series of DNJ analogs reveals
that the nature of the alkyl moiety greatly influences the
chemical chaperoning activity of the analog. Butyl DNJ
is inactive, DNJs with 9–10 carbon chains are active,
and dodecyl DNJ is predominantly inhibitory. DNJ alky-
lated with a chain capped by an adamantyl amide group
such as 27 shows an improved profile over the nonyl an-
alog 23, with a much broader window of utility and higher
levels of activity. Therefore, analogs containing this moi-
ety will be prepared for the other active compounds. Fur-
ther derivatization of promising compounds such as 31
and 32 should afford improved GC chemical chaperones
that retain the selectivity exhibited in Figure 5.
Compounds that are able to increase GC activity in tis-
sue culture have different activity profiles. It may be that
the inhibitory activity of some of the compounds is
masked by the quantity of enzyme that is rescued.
Thus, the same concentration of compound may be in-
hibitory or activating in various cell lines depending on
the quantity of compound and enzyme in the lysosomes.
Alternately, the observed profiles may be due to differ-
ences in dissociation rates of the GC-chemical chaper-
one complex in the lysosome. Extended time courses
with 27, 31, and 32 reveal that maximal activity is gener-
ally attained within a week and that the activity is re-
tained for at least 5 days after the chaperone is removed
from the media. When the chaperone is employed at or
below the concentration resulting in maximum GC activ-
ity, GC activity decreases steadily after chaperone re-
moval from the media. In contrast, when a chaperone
is utilized above the concentration resulting in maximum
GC activity, the activity of GC goes up after removal of
the chaperone from the media, owing at least in part to
partial GC inhibition.
Butyl DNJ 22, an FDA-approved inhibitor of substrate
biosynthesis, does not have an enhancing or inhibiting
effect on the GC variants tested. However, PDMP 34, an-other well-studied inhibitor of glucosylceramide synthe-
sis, is a modest GC chaperone. Collectively, these re-
sults suggest that it is conceivable to develop
substrate deprivation drugs that can also serve as
chemical chaperones. Administration of such com-
pounds could be doubly beneficial, reducing substrate
biosynthesis while elevating the activity of endogenous
enzyme.
Significance
We have previously shown that N-nonyl-deoxynojiri-
mycin can be used to increase the cellular activity of
N370S glucocerebrosidase, the variant that most com-
monly leads to Gaucher disease. Active site-directed
‘‘chemical chaperones,’’ such as N-nonyl-deoxynojiri-
mycin, are believed to stabilize misfolded proteins in
the endoplasmic reticulum, preventing proteasomal
degradation and increasing proper trafficking. Herein,
we report improved chemical chaperones that in-
crease the activity of not only N370S glucocerebrosi-
dase, but also G202R glucocerebrosidase, establish-
ing the generality of this approach. Since the G202R
glucocerebrosidase variant has been characterized
to be retained in the endoplasmic reticulum, the ob-
served activity increases are most likely due to im-
proved trafficking of this variant in the presence of
chemical chaperones. Active site-directed small mole-
cules failed to increase the activity of L444P glucocer-
ebrosidase, a mutation located in a domain remote
from the active site. Collectively, these data suggest
that certain glucocerebrosidase variants will be ame-
nable to chemical chaperoning by select active site-
directed small molecules, while others will likely
require small molecules that target the domain com-
promised by the mutation to stabilize them in the en-
doplasmic reticulum and enable proper trafficking to
the lysosome.
Experimental Procedures
Reagents
The following fluorogenic substrates were obtained from Sigma
(St. Louis, MO): 4-methylumbelliferyl-b-D-glucopyranoside, 4-meth-
ylumbelliferyl-b-D-glucuronide, 4-methylumbelliferyl phosphate,
4-methylumbelliferyl-b-D-galactopyranoside, 4-methylumbelliferyl-
a-D-galactopyranoside, 4-methylumbelliferyl-a-D-glucopyranoside,
and4-methylumbelliferyl-N-acetyl-b-D-glucosaminide.Minimumes-
sential medium with Earle’s salts and nonessential amino acids and
TrypLE Express were obtained from GIBCO-BRL (Grand Island, NY).
Fetal bovine serum, Dulbecco’s phosphate-buffered saline solution,
and glutamine pen-strep were obtained from Irvine Scientific (Santa
Ana, CA).
Cell Cultures
Primary skin fibroblast cultures were established from patients ho-
mozygous for either the N370S (c.1226A>G) mutation or the
G202R (c.721G>A) mutation. Type 2 Gaucher disease fibroblasts
containing the L444P (c.1448T>C) mutation (GM10915) and appar-
ently normal fibroblast cultures (GM05659, GM00498) were obtained
from the Coriell Cell Repositories (Camden, NJ). Fibroblasts were
maintained in minimum essential medium supplemented with 10%
fetal bovine serum and 1% glutamine pen-strep at 37ºC in 5%
CO2. Culture medium was replaced every 3–4 days, and monolayers
were passaged upon confluency with TrypLE Express. All cells used
in this study were between the 4th and 18th passages.
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The intact cell GC assay has been previously described [18]. Briefly,
cells were plated into 24-well assay plates. After cell attachment, the
media was replaced by media containing small molecules dissolved
in dimethyl sulfoxide. The final dimethyl sulfoxide concentration in
the media was less than 1%. No measurable change in GC activity
or cell viability as measured by trypan blue staining was observed
at these dimethyl sulfoxide concentrations (changes were within as-
say error, data not shown). Cells were incubated in media treated
with small molecule for the indicated amount of time before the ac-
tivity of the desired enzyme was assayed. The wells were washed
with phosphate-buffered saline, followed by substrate addition. Af-
ter incubation at 37ºC for the desired amount of time, the reaction
was stopped by lysing the cells with 0.2 M glycine buffer (pH 10.8).
Wild-type cells were typically incubated with assay substrate for
1 hr, but the other variants required longer incubation times due to
lower GC activity. GC activity was screened by using 2.5–5 mM
4-methylumbelliferyl-b-D-glucopyranoside in 0.2 M acetate buf-
fer (pH 4.0). Conduritol B epoxide (Toronto Research Chemicals,
Downsview, ON, Canada) was used as a control to evaluate the
extent of nonspecific GC activity [23]. The lysosomal enzymes
b-hexosaminidase, b-glucuronidase, b-galactosidase, and acid
phosphatase were assayed in cell lysates by using 4-methylumbel-
liferyl-N-acetyl-b-D-glucosaminide (3.2 mM), 4-methylumbelliferyl-
b-D-glucuronide (3.33 mM), 4-methylumbelliferyl-b-D-galactopyra-
noside (0.56 mM), and 4-methylumbelliferyl phosphate (3 mg/ml) in
10 mM citrate/phosphate (pH 4.2) [9]. The activity of a-galactosidase
A was determined by using 4-methylumbelliferyl-a-D-galactopyra-
noside and N-acetylgalactosamine, according to the method of
Mayes [34]. Lysosomal a-glucosidase activity was determined by
using 2.2 mM 4-methylumbelliferyl-a-D-glucopyranoside in 10 mM
citrate/phosphate (pH 4.4) [35]. Small molecules were evaluated in
triplicate at each concentration, and each molecule was assayed
at least three times. Total cell protein was measured by using Micro
BCA assay reagent (Pierce, Rockford, IL).
Small Molecules
N-(n-butyl) DNJ 22, N-(n-nonyl) DNJ 23, N-(7-Oxa-9,9,9-trifluoro-
nonyl) DNJ 24, N-(n-7-oxadecyl) DNJ 25, N-(n-dodecyl) DNJ 26, N-
(5-adamantane-1-yl-methoxy-pentyl) DNJ 28, and castanospermine
29 were obtained from Toronto Research Chemicals (Downsview,
ON, Canada). Octyl b-D-1-thioglucopyranoside 9 was obtained
from Sigma.
Compound 34 was generously provided by Dr. James Shayman
[26]. Compounds 15–17 were generously provided by Dr. Jared
Piper and Dr. Maarten Postema [36]. Compounds 2–8 were gener-
ously provided by Dr. Xingquan Ma and Dr. Qinghai Zhang.
The syntheses of 30 and 33 have been previously reported [18].
Compounds 10–14 were prepared by the addition of the appropri-
ate grignard reagent or deprotonated alkyne to 3,4,5-tris-benzyloxy-
6-benzyloxymethyl-tetrahydro-pyran-2-one. Subsequent treatment
of the resulting lactol with BF3OEt2 and deprotection by hydrogena-
tion afforded the desired b-C-glycoside [37–40].
Compounds 18–21 were prepared by the addition of the appropri-
ate deprotonated alcohol to toluene-4-sulfonic acid 3,4,5-tris-ben-
zyloxy-6-benzyloxymethyl-piperidin-2-ylmethyl ester. Subsequent
deprotection afforded the afforded the desired b-C-glycoside imino-
sugar [41, 42].
Following literature procedure, 1-deoxynojirimycin was prepared
from 2,3,4,6-tetra-O-benzyl-a-glucopyranose [43]. DNJ analog 27
was prepared via N-alkylation of 1-deoxynojirimycin with 6-bromo-
hexanoic acid methyl ester. The ester was deprotected and coupled
to 1-adamantylamine by using standard conditions to give 27.
2,5-Anhydro-imino-D-glucitol was prepared from 5-keto-D-fruc-
tose according to Reitz’s method [44, 45]. Isofagomine was pre-
pared as previously reported [46]. N-alkylated compounds 31 and
32 were prepared via reductive amination of N-octyl aldehyde with
2,5-anhydro-imino-D-glucitol and isofagomine, respectively.
Detailed syntheses and structural characterization for all prepared
small molecules are available in the Supplemental Data.
Supplemental Data
Supplemental Data including detailed syntheses and structural
characterization for all prepared small molecules are available at
http://www.chembiol.com/cgi/content/full/12/11/1235/DC1/.Acknowledgments
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